Form 4: Aptevo Therapeutics Director Converts Restricted Stock Units to Common Shares

Aptevo Therapeutics Inc. Director Daniel Abdun-Nabi converted one post-split Restricted Stock Unit into a common share on July 17, 2025, following a grant made in July 2024.

Summary

• Daniel Abdun-Nabi, a Director of Aptevo Therapeutics Inc. (APVO), acquired 1 share of common stock.
• This acquisition resulted from the conversion of 1 Restricted Stock Unit (RSU), which was equivalent to 925 pre-split RSUs.
• The RSU was granted on July 17, 2024, and vested in full one year later, on July 17, 2025.
• RSUs convert into common stock on a one-for-one basis (post-split).
• Following this transaction, Daniel Abdun-Nabi directly beneficially owns 1 common share and 0 derivative securities.

Sentiment

Score: 6

Explanation: The document reports a routine, expected insider transaction (vesting of RSUs) which results in a director increasing their direct ownership, generally viewed as a neutral to slightly positive signal of alignment with shareholder interests.

Positives

• A director's ownership of common stock increased, aligning management interests with shareholders.
• The transaction represents the vesting of previously granted equity compensation, a standard practice for incentivizing directors.
• The conversion of 925 pre-split RSUs into 1 post-split common share indicates the completion of a pre-scheduled equity event following a reverse stock split.

Future Outlook

The document details a future vesting event on July 17, 2025, for a Restricted Stock Unit granted on July 17, 2024, leading to the acquisition of one common share. This is a pre-scheduled event related to equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes, common across all industries for publicly traded companies. It reflects standard equity compensation practices for directors.

Stakeholder Impact

• Shareholders: Slight positive impact due to increased alignment of a director's interests with shareholders through direct stock ownership.

Next Steps

• The vesting and conversion of the RSU into common stock on July 17, 2025, represents the completion of a pre-determined equity compensation event.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Director, Equity Compensation, Beneficial Ownership, Reverse Stock Split